{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:23:59Z","timestamp":1790821439056,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.eprac.2020.09.011","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T21:23:36Z","timestamp":1612992216000},"page":"318-325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Chromogranin A in a Cohort of Pheochromocytomas and Paragangliomas: Usefulness at Diagnosis and as an Early Biomarker of Recurrence"],"prefix":"10.1016","volume":"27","author":[{"given":"Stefanie","family":"Parisien-La Salle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Proven\u00e7al","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Bourdeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.eprac.2020.09.011_bib1","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3390\/cancers11040586","article-title":"Chromogranin A in the laboratory diagnosis of pheochromocytoma and paraganglioma","volume":"11","author":"B\u00edlek","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.eprac.2020.09.011_bib2","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1210\/jc.2017-00992","article-title":"Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years","volume":"102","author":"Hamidi","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2020.09.011_bib3","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2020.09.011_bib4","doi-asserted-by":"crossref","first-page":"R135","DOI":"10.1530\/EJE-16-0189","article-title":"Management of endocrine disease: recurrence or new tumors after complete resection of pheochromocytomas and paragangliomas: a systematic review and meta-analysis","volume":"175","author":"Amar","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.eprac.2020.09.011_bib5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1055\/s-0031-1301339","article-title":"Long-term postoperative follow-up in patients with apparently benign pheochromocytoma and paraganglioma","volume":"44","author":"Amar","year":"2012","journal-title":"Horm Metab Res"},{"issue":"1","key":"10.1016\/j.eprac.2020.09.011_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2016.57577","article-title":"Chromogranin A - unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls","volume":"12","author":"Gut","year":"2016","journal-title":"Arch Med Sci"},{"issue":"1","key":"10.1016\/j.eprac.2020.09.011_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00005792-199101000-00003","article-title":"Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma","volume":"70","author":"Hsiao","year":"1991","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.eprac.2020.09.011_bib8","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2265.2006.02591.x","article-title":"The role of chromogranin A in the management of patients with phaeochromocytoma","volume":"65","author":"Grossrubatscher","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"10.1016\/j.eprac.2020.09.011_bib9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1210\/jc.2007-1354","article-title":"Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma","volume":"93","author":"Algeciras-Schimnich","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2020.09.011_bib10","first-page":"344","article-title":"Chromogranin A immunoradiometric assay in diagnosis of pheochromocytoma: comparison with plasma metanephrines and 123I-MIBG scan","volume":"50","author":"Giovanella","year":"2006","journal-title":"Q\u00a0J Nucl Med Mol Imaging"},{"issue":"7","key":"10.1016\/j.eprac.2020.09.011_bib11","first-page":"993","article-title":"Chromogranin A assay and (131)I-MIBG scintigraphy for diagnosis and follow-up of pheochromocytoma","volume":"42","author":"d\u2019Herbomez","year":"2001","journal-title":"J\u00a0Nucl Med"},{"issue":"2","key":"10.1016\/j.eprac.2020.09.011_bib12","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1365-2265.2010.03914.x","article-title":"Plasma chromogranin A levels are increased in a small portion of patients with hereditary head and neck paragangliomas","volume":"74","author":"van Duinen","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"10.1016\/j.eprac.2020.09.011_bib13","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0033","article-title":"European Society of Endocrinology clinical practice guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma","volume":"174","author":"Plouin","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2020.09.011_bib14","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/MPA.0b013e31828e34a4","article-title":"Consensus guidelines for the management and treatment of neuroendocrine tumors","volume":"42","author":"Kunz","year":"2013","journal-title":"Pancreas"},{"issue":"2","key":"10.1016\/j.eprac.2020.09.011_bib15","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000225948","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biochemical markers","volume":"90","author":"O\u2019Toole","year":"2009","journal-title":"Neuroendocrinology"},{"issue":"4","key":"10.1016\/j.eprac.2020.09.011_bib16","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/eci.12245","article-title":"Clinical utility of chromogranin A in SDHx-related paragangliomas","volume":"44","author":"Zuber","year":"2014","journal-title":"Eur J Clin Invest"},{"issue":"21","key":"10.1016\/j.eprac.2020.09.011_bib17","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1056\/NEJM199311183292103","article-title":"Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease","volume":"329","author":"Neumann","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2020.09.011_bib18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ctrv.2010.07.002","article-title":"Malignant pheochromocytomas and paragangliomas - the importance of a multidisciplinary approach","volume":"37","author":"Andersen","year":"2011","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.eprac.2020.09.011_bib19","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s12020-010-9422-5","article-title":"Malignant pheochromocytoma: predictive factors of malignancy and clinical course in 16 patients at a single tertiary medical center","volume":"39","author":"Szalat","year":"2011","journal-title":"Endocrine"},{"issue":"3","key":"10.1016\/j.eprac.2020.09.011_bib20","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000179900","article-title":"Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors","volume":"89","author":"Welin","year":"2009","journal-title":"Neuroendocrinology"},{"issue":"6","key":"10.1016\/j.eprac.2020.09.011_bib21","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1161\/01.HYP.36.6.1045","article-title":"Malignant pheochromocytoma. Chromaffin granule transmitters and response to treatment","volume":"36","author":"Rao","year":"2000","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.eprac.2020.09.011_bib22","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/s41440-019-0339-y","article-title":"Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy","volume":"43","author":"Parasiliti-Caprino","year":"2020","journal-title":"Hypertens Res"},{"issue":"8","key":"10.1016\/j.eprac.2020.09.011_bib23","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/bjc.2011.380","article-title":"Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours","volume":"105","author":"Korse","year":"2011","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.eprac.2020.09.011_bib24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000321535","article-title":"Effect of proton-pump inhibitor therapy on serum chromogranin A level","volume":"84","author":"Pregun","year":"2011","journal-title":"Digestion"},{"issue":"2","key":"10.1016\/j.eprac.2020.09.011_bib25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1530\/EJE-17-0077","article-title":"Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma","volume":"177","author":"Rao","year":"2017","journal-title":"Eur J Endocrinol"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2048379X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2048379X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:09:17Z","timestamp":1761516557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X2048379X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1530891X2048379X"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2020.09.011","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chromogranin A in a Cohort of Pheochromocytomas and Paragangliomas: Usefulness at Diagnosis and as an Early Biomarker of Recurrence","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2020.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}